Clinical Trials Logo

Advanced Cancer clinical trials

View clinical trials related to Advanced Cancer.

Filter by:

NCT ID: NCT00507962 Completed - Advanced Cancer Clinical Trials

Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement

Start date: March 2005
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is find the highest safe dose of cisplatin that can be given with liposomal doxorubicin in the treatment of advanced cancer involving the liver. PRIMARY Objectives: To determine the toxicity and safety of a monthly cytotoxic regimen combining intraarterial hepatic (HAI) cisplatin with systemic intravenous liposomal doxorubicin in patients with cancer metastatic to the liver. SECONDARY Objectives: To document in a descriptive fashion the antitumor efficacy of monthly hepatic intraarterial cisplatin in combination with systemic liposomal doxorubicin.

NCT ID: NCT00507754 Completed - Advanced Cancer Clinical Trials

Latent Tuberculosis Infection in Cancer Patients

Start date: June 2007
Phase: N/A
Study type: Observational

Primary Objective: 1. To evaluate the performance of the new T-SPOT.TB test and the conventional TST for screening of Latent Tuberculosis infections in patients with cancer and those undergoing Hematopoietic Stem Cell Transplant. Secondary Objectives: 1. To examine the factors associated with positive response to T-SPOT.TB and the TST (tuberculin skin test) in patients with anergy. 2. To determine the impact of immunosuppressive and antineoplastic therapy on the screening performance of T-SPOT.TB and the TST in cancer patients.

NCT ID: NCT00505544 Completed - Advanced Cancer Clinical Trials

Measuring Sleep Disturbance Among Cancer Patients

Start date: August 2005
Phase:
Study type: Observational

Objectives: Primary Objectives: 1. To establish concurrent criterion-related validity of the Brief Sleep Disturbance Scale (BSDS) by correlating the scale with the Pittsburgh Sleep Quality Index. 2. To evaluate the construct validity of the BSDS through exploratory factor analysis. 3. To examine possible predictors of sleep disturbance. 4. To evaluate the reliability of the BSDS using Cronbach's coefficient alpha and test-retest reliability. 5. To evaluate the sensitivity of the BSDS by administering it to the same group of patients (n = 60) prior to treatment with a regimen associated with sleep disturbance, during 4 weeks of treatment, and upon completion of treatment. 6. To evaluate the psychometric properties of the BSDS in a sample of community dwelling adults. Secondary Objective: 1. To obtain pilot data from a small sample of patients who will wear an actigraph for one week.

NCT ID: NCT00504985 Terminated - Fatigue Clinical Trials

Fatigue in Emergency Center Patients

Start date: August 2005
Phase: N/A
Study type: Observational

1. To describe fatigue severity and its related symptom clusters in cancer patients who are seeking emergency care for fever, pain, shortness of breath, or cancer therapy-related gastrointestinal toxicities. 2. To describe inflammatory cytokine profiles in cancer patients who are seeking emergency care for fever, pain, shortness of breath, or cancer therapy-related gastrointestinal toxicities. 3. To determine the type of cytokines that are associated with fatigue severity in cancer patients, with or without cancer treatment, in the early phase of infection, as well as in patients with pain, shortness of breath, or cancer therapy-related gastrointestinal toxicities.

NCT ID: NCT00493714 Completed - Advanced Cancer Clinical Trials

Delirium Recall in Advanced Cancer Patients

Start date: July 2005
Phase: N/A
Study type: Observational

Primary Objectives: 1. To determine the proportion of patients who experience partial or complete recollection of symptoms of delirium and the level of distress associated with this recall. 2. To determine caregiver's level of distress associated with the patient's episode of delirium.

NCT ID: NCT00489593 Completed - Weight Loss Clinical Trials

Olanzapine in Patients With Advanced Cancer and Weight Loss

Start date: October 2006
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest tolerable dose of the drug Olanzapine that can be given to patients with advanced cancer who are experiencing weight loss. Researchers want to find out if Olanzapine can help decrease weight loss in patients who are experiencing it because of cancer. How this drug affects performance status, cancer-related symptoms, and nutritional status in patients with advanced cancer will also be studied.

NCT ID: NCT00488072 Active, not recruiting - Insomnia Clinical Trials

Effects of Mirtazapine on Appetite in Advanced Cancer Patients

Start date: September 20, 2006
Phase: Phase 2
Study type: Interventional

Primary objective: This is a preliminary study to determine if Mirtazapine in comparison to placebo will improve appetite in advanced cancer patients with anorexia and weight loss. An improvement of appetite is defined as a decrease of 2 in the appetite score from baseline on the Edmonton Symptom Assessment Scale (ESAS) at day 15 (+/-3 days). Secondary objective-A: To determine if Mirtazapine in comparison to placebo will improve insomnia ( as measured by Pittsburgh Sleep Quality Index) on day 15 ( +/- 3 days), and day 29 ( +/- 3 days) Secondary objective - B: To determine if Mirtazapine in comparison to placebo will improve other common symptoms such as pain, nausea and fatigue( as measured by ESAS), depression and anxiety ( as measured by Hospital Anxiety and Depression scale), and quality of life ( as measured by Functional Assessment of Anorexia/Cachexia Therapy ) in advanced cancer patients with anorexia/cachexia, on days 15 (+/-3 days), and 29 (+/-3 days) Other Objectives: To provide exploratory data on the effects of Mirtazapine on weight gain, and preservation/gain lean muscle mass ( anthropometric measurements and Bioelectric Impedance), on days 15 (+/-3 days), and 29 (+/-3 days). To provide exploratory data on the effects of a Mirtazapine dose increase to 30 mg on decreased side effects of drug and increased appetite on day 29 (+/-3 days).

NCT ID: NCT00477243 Completed - Advanced Cancer Clinical Trials

Locus of Control and Spirituality in Palliative Care Patients

Start date: June 3, 2004
Phase: N/A
Study type: Observational

Primary Objectives: 1. To determine whether the degree of spirituality/religiosity as determined by the Duke University Religion Index and Functional Assessment of Chronic Illness Therapy-Spiritual Well Being Scale (FACIT-Sp) correlates with internal locus of control as determined by the Locus of Control Scale. 2. To determine the relationships among spiritual-well being, religiosity, hope, depression, and culture, socioeconomic status, and gender in a palliative care setting. 3. To determine if hope and depression in palliative care patients are affected by the degree of intrinsic and extrinsic spirituality/religiosity. 4. To determine if patients who believe in predestination correlate with decreased locus of control, but improved quality of life and degree of religiosity.

NCT ID: NCT00450541 Completed - Advanced Cancer Clinical Trials

Fatigue Experience in Cancer Patients

Start date: March 2007
Phase: N/A
Study type: Observational

The goal of this research study is to learn what it is like when a patient with cancer has fatigue, as well as how these patients define fatigue. Researchers want to use this information to create questionnaires that may more accurately measure fatigue and its effects in patients with cancer.

NCT ID: NCT00438620 Completed - Advanced Cancer Clinical Trials

The Feasibility of Physical Activity in Advanced Cancer Patients

Start date: October 2006
Phase: N/A
Study type: Observational

Physical activity has been shown to have a positive effect on several quality of life outcomes in cancer patients, but few existing studies have focused on the end stages of cancer. The aim of this pilot study is to test the feasibility of a physical activity intervention in advanced cancer patients, from which data can be used to design a randomized controlled trial if results are encouraging.